METTL17 and colorectal carcinoma: Western blot and immunostaining analysis demonstrated that METTL17-knockdown tumors displayed reduced expression of β-Catenin, a marker of CRC progression, while the protein level of PCNA and the number of Ki-67 positive cells remained unchanged (Fig. 3D, E, F).